Genovis reports interim results for January-June 2026
Net sales grew 19% in Q2, boosted by acquisition and strong genomics; underlying profitability strengthened.
See the latest news and media coverage for Genovis. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company providing biopharmaceutical research tools
genovis.comLast updated
In short: Genovis released KRysin data, posted 19% Q2 growth, acquired KPL, and signed an EndoS2 deal.
Net sales grew 19% in Q2, boosted by acquisition and strong genomics; underlying profitability strengthened.
The new immunoglobulin-binding product expands the portfolio in advanced proteomics and diagnostics through unique antigen release.
The acquisition adds KPL's proprietary precision proteases for mass spectrometry-based protein analysis, strengthening Genovis' coverage in proteomics.
The meeting approved financial statements, re-elected board, authorized share issuance, and updated remuneration guidelines.
Arctic initiates coverage of Genovis with a buy recommendation and a target price of 28 SEK...
Jul. 23 Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least...
kr 20.95 SEK-0.05-0.24% ...
Track Genovis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Genovis and other trending companies.